12
ALL2
Cycle Pharmaceuticals2
Glenmark Pharmaceuticals3
Novartis Pharmaceuticals Corporation4
VYNE Therapeutics1
Zydus LifesciencesYear
12
ALL2
20237
20221
20212
2020DEALS // DEV.
12
ALL12
DevelopmentsCountry
12
ALL3
INDIA3
SWITZERLAND4
U.S.A2
UNITED KINGDOM12
ALL12
InapplicableTherapeutic Area
12
ALL4
Dermatology8
NeurologyStudy Phase
12
ALL8
Approved FDF4
Phase I/ Phase IIDeal Type
12
ALL12
InapplicableProduct Type
12
ALL12
Other Small MoleculeDosage Form
12
ALL6
Oral Capsule2
Oral Tablet, Orally Disintegrating4
Topical GelLead Product
12
ALL8
Fingolimod Hydrochloride4
Tofacitinib CitrateTarget
12
ALL4
JAK8
S1PRLead Product(s) : Fingolimod Hydrochloride
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Tascenso (fingolimod) is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of MS, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 yea...
Product Name : Tascenso
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 13, 2023
Lead Product(s) : Fingolimod Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fingolimod Hydrochloride
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Tascenso (fingolimod) is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of MS, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 yea...
Product Name : Tascenso
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 17, 2023
Lead Product(s) : Fingolimod Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fingolimod Hydrochloride
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Glenmark Pharmaceuticals launches Fingolimod Capsules, 0.5 mg in the US
Details : Fingolimod, an orally available immunomodulatory drug, is a sphingosine 1-phosphate receptor modulator used to treat patients with the relapsing-remitting form of multiple sclerosis (MS).
Product Name : Gilenya-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 31, 2022
Lead Product(s) : Fingolimod Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tofacitinib Citrate,Fingolimod Hydrochloride
Therapeutic Area : Dermatology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Mean reduction in ADSI score from baseline was -4.05 (-60.62% mean reduction) for FMX114 (tofacitinib) treated lesions compared to -3.48 (-51.32% mean reduction) for vehicle treated lesions at week 4 (p=0.228, OC, ITT).
Product Name : FMX114
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 08, 2022
Lead Product(s) : Tofacitinib Citrate,Fingolimod Hydrochloride
Therapeutic Area : Dermatology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fingolimod Hydrochloride
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : GILENYA (fingolimod) is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults and children 10 years of a...
Product Name : Gilenya
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 21, 2022
Lead Product(s) : Fingolimod Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tofacitinib Citrate,Fingolimod Hydrochloride
Therapeutic Area : Dermatology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : FMX114, an investigational combination gel formulation of tofacitinib and fingolimod, demonstrated a statistically significant reduction in both absolute and percent change in ADSI score compared to vehicle at week 2.
Product Name : FMX114
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 04, 2022
Lead Product(s) : Tofacitinib Citrate,Fingolimod Hydrochloride
Therapeutic Area : Dermatology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fingolimod Hydrochloride
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Gilenya® (fingolimod), an oral, once-daily at 0.5mg and 0.25mg versus once-daily subcutaneous injections of glatiramer acetate 20mg in reducing disease activity over 12 months in patients with relapsing remitting multiple sclerosis (RRMS).
Product Name : Gilenya
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 21, 2022
Lead Product(s) : Fingolimod Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tofacitinib Citrate,Fingolimod Hydrochloride
Therapeutic Area : Dermatology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : FMX114 (tofacitinib), is VYNE’s proprietary investigational combination gel formulation of tofacitinib and fingolimod, which has been designed to address both the source and cause of inflammation in AD.
Product Name : FMX114
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 17, 2022
Lead Product(s) : Tofacitinib Citrate,Fingolimod Hydrochloride
Therapeutic Area : Dermatology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fingolimod Hydrochloride
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : HEC Pharma filed the ANDA to get generic version of Novartis' Gilenya® (fingolimod), in response to that Novartis filed litigation against ANDA filers for US Patent No. 9,187,405 and extend the validity of Gilenya till 2027.
Product Name : Gilenya
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 01, 2022
Lead Product(s) : Fingolimod Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tofacitinib Citrate,Fingolimod Hydrochloride
Therapeutic Area : Dermatology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : FMX114 is VYNE’s proprietary investigational combination gel formulation of tofacitinib and fingolimod for the treatment of mild-to-moderate atopic dermatitis (AD).
Product Name : FMX114
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 19, 2021
Lead Product(s) : Tofacitinib Citrate,Fingolimod Hydrochloride
Therapeutic Area : Dermatology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable